Market Place
Sourcing Support
AB Science Updates On Masitinib In Multiple Sclerosis
23 Sep 2024 //
GLOBENEWSWIRE
AB Science announces results of Phase 2 study evaluating masitinib in Covid-19
08 Jul 2024 //
GLOBENEWSWIRE
AB Science Updates On Masitinib Application For ALS
28 Jun 2024 //
GLOBENEWSWIRE
AB Science Updates On Masitinib Application For ALS Approval
29 May 2024 //
GLOBENEWSWIRE
AB Science Masitinib EU Patent To 2036 In Mastocytosis
13 May 2024 //
GLOBENEWSWIRE
AB Announces that HC has Granted Eligibility for Reconsideration for Masitinib
03 Apr 2024 //
GLOBENEWSWIRE
AB Science: New research shows that masitinib limits neuronal damage
13 Mar 2024 //
GLOBENEWSWIRE
AB Science announces that Health Canada has issued a NON/w for masitinib
26 Feb 2024 //
GLOBENEWSWIRE
AB Science announces an update in the MAA of masitinib
26 Jan 2024 //
GLOBENEWSWIRE
AB Science receives notice of allowance for European patent covering masitinib
15 Jan 2024 //
GLOBENEWSWIRE
AB Science will host a live webcast on Thursday November 30, 2023
28 Nov 2023 //
GLOBENEWSWIRE
AB Science receives Notice of Allowance for European patent covering masitinib
26 Jun 2023 //
GLOBENEWSWIRE
AB Science announces issuance of a Canadian patent for masitinib
01 Jun 2023 //
GLOBENEWSWIRE
AB Science: Results of masitinib for a scientific platform presentation at AAN
12 Apr 2023 //
GLOBENEWSWIRE
AB Science has received approval from the USFDA for Ph3 study with masitinib
30 Dec 2022 //
GLOBENEWSWIRE
Masitinib receives orphan drug status for the treatment of ALS in Switzerland
27 Dec 2022 //
GLOBENEWSWIRE
AB Science receives NOD from Health Canada for masitinib in the treatment of ALS
13 Dec 2022 //
GLOBENEWSWIRE
AB Science receives FDA authorization to initiate Phase 3 study with masitinib
21 Nov 2022 //
GLOBENEWSWIRE
AB Science receives first agencies authorizations Ph3 clinical study masitinib
10 Oct 2022 //
GLOBENEWSWIRE
AB Science announced publication of results from its positive study of masitinib
07 Jun 2022 //
GLOBENEWSWIRE
AB Science announces that Health Canada has started the review of masitinib
26 May 2022 //
GLOBENEWSWIRE
AB Science announces publication of masitinib positive pivotal Phase 3 trial
22 Feb 2022 //
GLOBENEWSWIRE
Health Canada grants AB Science authorization to file NDS for masitinib in ALS
21 Feb 2022 //
GLOBENEWSWIRE
AB Science granted authorization to initiate Phase III trial of masitinib
03 Jan 2022 //
GLOBENEWSWIRE
AB Science announces dosing of first patient in Phase 2 trial of masitinib’s
29 Nov 2021 //
GLOBENEWSWIRE
AB Science received authorization from the FDA to resume patient masitinib
18 Nov 2021 //
GLOBENEWSWIRE
AB Science receives FDA authorization to start clinical devP program masitinib
04 Oct 2021 //
GLOBENEWSWIRE
AB Science receives FDA authorization for masitinib in MCAS
04 Oct 2021 //
BIOSPACE
AB Science receives FDA authorization to start clinical devP program masitinib
04 Oct 2021 //
GLOBENEWSWIRE
AB Science receives FDA authorization for masitinib in MCAS
04 Oct 2021 //
BIOSPACE
AB Science to begin second Phase II Covid-19 clinical trial with masitinib
29 Sep 2021 //
CLINICALTRIALSARENA
AB Science announced Positive Data on masitinib at Spanish Society of Neurology
20 Sep 2021 //
GLOBENEWSWIRE
AB Science announced that it has received new authorizations Ph 3 of masitinib
14 Sep 2021 //
GLOBENEWSWIRE
AB Science announced results from masitinib study AB12003 in prostate cancer
13 Sep 2021 //
GLOBENEWSWIRE
AB Science: 2nd authorization for patient enrollment in PIII study of masitinib
25 Aug 2021 //
GLOBENEWSWIRE
AB Science receives nod for patient enrollment in Phase 3 masitinib study in ALS
23 Aug 2021 //
GLOBENEWSWIRE
AB Science announces results from masitinib study AB12005 presented at 2021 ASCO
10 Jun 2021 //
PRESS RELEASE
AB Science is providing a summary of the live webcast held on June 3, 2021
08 Jun 2021 //
GLOBENEWSWIRE
AB Science announces that confirmatory Phase 3 study AB12005
04 Dec 2020 //
GLOBENEWSWIRE
AB Science announces positive top-line Phase 3 results for oral masitinib
20 Oct 2020 //
GLOBENEWSWIRE
AB Science announces that new results published in the peer-reviewed Journal
07 Jul 2020 //
GLOBENEWSWIRE
AB Science granted authorization by ANSM initiate Ph2 study masitinib
06 May 2020 //
GLOBENEWSWIRE
AB Science announces positive top-line Phase 2B/3 results for oral masitinib
20 Feb 2020 //
GLOBENEWSWIRE
FDA green-lights U.S. patient enrollment in masitinib Phase 3 study
08 Jan 2020 //
GLOBE NEWSWIRE
FDA green-lights U.S. patient enrollment in masitinib Phase 3 study
07 Jan 2020 //
GLOBE NEWSWIRE
FDA green-lights U.S. patient enrollment in masitinib Phase 3 study
07 Jan 2020 //
GLOBE NEWSWIRE
Orion takes repurposed heart drug into phase 3 for ALS
06 Jul 2018 //
FIERCE BIOTECH
AB Sciences decides against re-examination of masitinib filing
29 May 2018 //
PHARMA TIMES
CHMP rejects AB Science’s ALS drug
24 Apr 2018 //
PHARMA TIMES
EMA committee says AB Science’s Masitinib should not be approved GCP failings
23 May 2017 //
IN PHARMATECHNOLOGIST
AB Science suspends French masitinib trials after ANSM finds deviations
15 May 2017 //
IN PHRAMATECHNOLOGIST
AB Science claims first with motor neurone disease therapy
23 Mar 2017 //
PMLIVE
Experimental ALS drug wins EU orphan status
10 Aug 2016 //
PHARMATIMES
